bioihbjkbjnl/mcl2 huggingface dataset:
The Effects of Mental Practice Combined With Proprioceptive Neuromuscular Facilitation on Muscle Strength of Upper Limb and Hand Grip
Condition: Motor Activity; Physical Activity; Neuromuscu
Study type: Interventional

Summary: 
      Influence of mental practice and proprioceptive neuromuscular facilitation on muscle strength
      of upper limb and hand grip will be measured in 30 to 50 healthy students with right dominant
      hand, Their age will be ranged from 18 to 26 years old. Subjects will randomly assigned to
      either proprioceptive neuromuscular facilitation (PNF) group or proprioceptive neuromuscular
      facilitation with mental practice (PNFMP) group.
    

Detailed description: 
      PNF group: 15 - 25 individuals, these subjects will receive only PNF training. PNFMP: 15
      individuals, these subjects will receive PNF training with MP. Training program will be
      conducted for every group for 5 weeks with 3 sessions x 30 min per week. Electromyography
      (EMG) device will be used to measure the electrical activity of muscles using surface
      electrodes. Hydraulic hand dynamometer will be used to measure hand grip strength.
    

Intervention name(s): PNF; PNFMP
Intervention type(s): Procedure; Procedure
Intervention description(s): proprioceptive neuromuscular facilitation training; proprioceptive neuromuscular facilitation training and mental practice technique
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: There are two group of subjects: PNF group will receive only PNF training PNFMP group: will receive PNF training and mental pracice technique
Masking: None (Open Label)
Primary purpose: Health Services Research
Cardiac Care Solution for Coronary Disease Follow up
Condition: ST Segment Elevation Myocardial Infarction; Non-ST Segment Elevation Myocardial Infarction; Unstable Angina
MeSH terms: Myocardial Infarction; ST Elevation Myocardial Infarction; Angina, Unstable; Infarction
Study type: Interventional

Summary: 
      This is a prospective, randomized controlled trial. The aim of the study is to evaluate the
      impacts of a cardiac post-discharge management solution in the secondary prevention of
      Coronary Artery Disease (CAD).
    

Detailed description: 
      The aim of the study is to evaluate the impacts of a cardiac post-discharge management
      solution in the population of cardiovascular (CVD) patients who were discharged from the
      hospital. The objectives include two parts:

      Objective 1: Assess the feasibilities of using the solution by means of questionnaire.

      Objective 2: Evaluate the impacts of the solution in the secondary prevention of Coronary
      Artery Disease (CAD).

      Primary outcome: Compliance of coronary disease secondary prevention at 12 months.

      Secondary outcome: Compliance of coronary disease secondary prevention at 6 months.
      Self-management behavior evaluation at the 6 and 12 months. Medication compliance at 6 and 12
      months assessed by self-reporting questionnaire. Control rates of risk factors at the 6 and
      12 months (serum LDL-C, blood pressure, fasting serum glucose); quality of life at the 6 and
      12 months (EQ-5D, Seattle angina questionnaire); MACE (Major Adverse Cardiac Event) within 12
      months (death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for cardiac
      reason, unplanned coronary revascularization).

      The study will be a two arm, randomized control study. The intervention group will use an
      application installed on a Pad besides standard outpatient follow up, while the control group
      will receive standard outpatient follow up.
    

Intervention name(s): BAMA solution
Intervention type(s): Device
Intervention description(s): Use of BAMA cardiac post-discharge management solution for patients education and follow up management
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Prevention
A Clinical Study With MT-102 in Subjects With Cancer Cachexia
Condition: Cancer Cachexia
MeSH terms: Wasting Syndrome; Cachexia
Study type: Interventional
Phase: Phase 2

Summary: 
      A phase II clinical study to evaluate MT-102 administered over a sixteen week period in
      subjects with cachexia related to non-small cell lung cancer and colorectal cancer
    

Detailed description: 
      Cachexia is a wasting disease, associated with significant morbidity and mortality,
      accompanying a wide range of serious illnesses, for which there are currently no widely
      approved therapeutic agents. Cachexia is defined as weight loss, associated with a chronic
      underlying disease, of at least 5% in 12 months or less. It is associated with fatigue, loss
      of muscle strength, a low fat free index and neurohormonal and biochemical abnormalities.

      Cancer cachexia occurs in about a third of all patients with cancer and has been estimated to
      be the direct cause of death in up to 20% of all cancer related deaths. As with other solid
      tumours, colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) have relatively high
      incidences of cachexia, approximately 28% and 34% respectively.Through its combined
      pharmacological actions, MT-102 has a multi-functional effect upon three potential
      pharmacological targets, each of which is relevant for cancer cachexia
    

Intervention name(s): MT-102
Intervention type(s): Drug
Intervention description(s): BETA BLOCKER
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Cachexia; Cancer
A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)
Condition: MPS 7; Sly Syndrome; Mucopolysaccharidosis; MPS VII
MeSH terms: Mucopolysaccharidoses; Mucopolysaccharidosis VII
Study type: Interventional
Phase: Phase 3

Summary: 
      The Phase 3 study will use a novel randomized, intra-subject placebo-controlled, single
      crossover design, referred to as Blind Start, to evaluate the safety and efficacy of UX003.
      The Blind Start is a novel design whereby participants will be randomized to 1 of 4 groups,
      each representing a different treatment sequence, and will cross over to UX003 at different
      pre-defined time points in a blinded manner. All groups will receive a minimum of 24 weeks
      treatment with 4 mg/kg UX003 every other week (QOW).
    


Intervention name(s): UX003; Placebo
Intervention type(s): Drug; Other
Intervention description(s): UX003 is a sterile concentrate formulation of rhGUS for intravenous infusion; Placebo consisting of the UX003 formulation buffer (without rhGUS)
Other intervention name(s): recombinant human beta-glucuronidase; rh-β-glucuronidase; rhGUS; Reference therapy
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: MPS 7; Sly Syndrome; Mucopolysaccharidosis; MPS VII; Enzyme Replacement Therapy; Mucopolysaccharidosis type 7; rare disease; lysosomal storage disease; metabolic disorder
Effects of a Multi-Ingredient Pre-Workout Supplement on Energy Expenditure During Running
Condition: Healthy
Study type: Interventional

Summary: 
      The primary purpose of this study was to examine the acute effects of one versus two doses of
      a multi-ingredient pre-workout supplement on energy expenditure during moderate-intensity
      treadmill running. In addition, our second aim was to investigate the responses of associated
      metabolic factors (i.e. substrate utilization, measures of gas exchange), perceived exertion,
      and resting cardiovascular variables with one and two doses of the pre-workout supplement.
    

Detailed description: 
      This study utilized a randomized, double-blind, placebo-controlled, within-subjects crossover
      design (Figure 1). Each subject was required to visit the laboratory on five occasions with
      72-96 hours between sessions. During the first laboratory visit, each subject performed an
      incremental test on a treadmill to familiarize the subjects with the testing procedures. For
      the second laboratory visit, each subject performed an incremental treadmill test to
      exhaustion to determine their ventilatory threshold (VT). The third laboratory visit was
      completed in the morning (06:00-09:00) and required subjects to consume a standardized meal
      after fasting overnight (8 hours) and sat quietly for 30 minutes before baseline heart rate
      and blood pressure values were recorded. The subjects were then randomly assigned to ingest
      the supplement (one or two doses) or placebo and sit quietly for another 30 minutes. The
      ingredients of the supplement (Cellucor, Bryan, TX) are provided in Table 1. The placebo was
      non-energetic and controlled for similar appearance and taste. At the 15-minute and 30-minute
      post-ingestion periods (of the pre-workout supplement or placebo), resting heart rate and
      blood pressure were recorded for a second and third time, respectively. Subjects then
      performed a 30-minute constant-velocity treadmill run at 90% of their VT. The subjects then
      returned to the laboratory for their fourth and fifth visits to ingest the remaining
      substances (1-dose, 2-dose, or placebo) and undergo the same testing procedures (including
      time of day) as the third visit. Each subject recorded 2-day food logs (MyFitnessPal, Inc.,
      USA) prior to each laboratory visit.
    

Intervention name(s): One dose pre-workout condition; Two dose pre-workout condition; Placebo condition
Intervention type(s): Dietary Supplement; Dietary Supplement; Dietary Supplement
Intervention description(s): one dose of a multi-ingredient pre-workout supplement; two doses of a multi-ingredient pre-workout supplement; one dose of a placebo
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Other
Keywords: caffeine; substrate utilization; thermogenic; fat oxidation
Resistant Starch and Whey Protein on Energy Metabolism
Condition: Weight Loss
MeSH terms: Weight Loss
Study type: Interventional

Summary: 
      Recent evidence shows that dietary supplementation with resistant starch (RS) increases fat
      catabolism and resting energy expenditure and decreases plasma insulin and glucose responses
      as well as the gut-derived hormone, glucose-dependent insulinotropic polypeptide (GIP).
      Consumption of whey protein has also been shown to increase energy expenditure and favorably
      affect gut hormones. Thus, investigators tested consumption of both RS and whey protein on
      energy expenditure and gut hormones in lean and obese women and men.
    

Detailed description: 
      Consumed separately, resistant starch (RS) and whey protein (WP) favorably affect energy
      metabolism and gut hormones, as well as suppress feelings of hunger. These findings are
      important because release of certain gut hormones (i.e., GIP) is associated with a lower
      resting energy expenditure (REE) in healthy humans. Interestingly, a recent study showed that
      ingestion of RS reduces postprandial GIP and increases postprandial REE and fat utilization
      in healthy men and therefore may be an effective strategy in weight management. Thus, there
      is a need to replicate these findings in a healthy cohort of lean and obese women and men.

      The purpose of this study was to examine the effects of RS on the number of calories burned
      after eating a meal, as well as specific hormones that are released from the stomach and
      intestines following meal ingestion in healthy lean and obese women and men. Investigators
      used a single ingestion of a meal supplemented with or without the resistant starch and whey
      protein.
    

Intervention name(s): waxy maize starch; waxy maize starch and Whey Protein; Resistant Starch; resistant starch and whey protein
Intervention type(s): Other; Other; Other; Other
Intervention description(s): pancake test meal with waxy maize starch only; pancake test meal with waxy maize starch and whey protein; pancake test meal with resistant starch only; pancake test meal with resistant starch and whey protein
Other intervention name(s): WMS; WMS-WP; RS; RS-WP
Allocation: Randomized
Intervention model: Single Group Assignment
Masking: Single (Participant)
Primary purpose: Other
Keywords: fat oxidation; hunger; resistant starch; whey protein
Biomarkers in Endometriosis
Condition: Endometriosis
MeSH terms: Endometriosis
Study type: Observational [Patient Registry]

Summary: 
      Endometriosis is a common gynecological benign disease which significantly compromise quality
      of life in patients and is a major cofactor of infertility. With the proteomic approach the
      investigators will search for proteins with significantly different levels in peritoneal
      fluid, serum and uterine fluid samples of women with endometriosis versus control group.
      Results will be validate using ELISA aproach.
    

Detailed description: 
      Informed consent will be obtained from all individual participants included in the study.
      Blood sample will be obtained the day before laparoscopic surgery during regular clinical
      preoperative procedures. Peritoneal fluid and uterine fluid will be obtained during regular
      laparoscopic procedure indicated for infertility, the exact protocol of sample obtaining will
      be revealed after publication of results. The aim of the study was to identify potential
      diagnostic and predictive biomarkers or drug targets.
    

Intervention name(s): proteomic analyses, ELISA validation of peritoneal fluid, blood and uterine fluid sample
Intervention type(s): Diagnostic Test
Intervention description(s): All samples were collected during laparoscopy, before any intraabdominal procedure was done. Indication for surgery was clinical (not for research purpose). All sample collection procedures was mimic regular clinical procedures.
Observational model: Case-Control
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Patients with primary infertility or endometriosis with clinical indication for surgery.
      
Biospecimen description: 
      peritoneal fluid precipitate, serum precipitate, uterine fluid precipitate
    
Keywords: Endometriosis; Biomarkers
Millimeter Wave Therapy (MWT) for Analgesia After Total Knee Replacement
Condition: Pain; Acute Pain
MeSH terms: Acute Pain
Study type: Interventional
Phase: Phase 2/Phase 3

Summary: 
      The aim of the study was to test whether the exposure to electromagnetic millimeter waves -
      Millimeter Wave Therapy (MWT) is effective for relief of acute postoperative pain in patients
      after elective unilateral total knee arthroplasty (TKA)
    


Intervention name(s): Generator of electromagnetic millimeter waves
Intervention type(s): Device
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double
Primary purpose: Treatment
Keywords: Postoperative pain; analgesia; total knee arthroplasty
Laryngeal Mask Airway for Adenoidectomies (LMAA)
Condition: Adenoidectomy Surgery; Flexible-Laryngeal Mask Airway
Study type: Interventional
Phase: Phase 4

Summary: 
      The current study retrospectively assesses laryngeal mask airway use during pediatric
      adenoidectomies in terms of patient safety, comfort, complications and surgeon satisfaction
      levels.
    


Intervention name(s): Flexible-Laryngeal Mask Airway
Intervention type(s): Other
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Health Services Research
Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?
Condition: Relapsing Remitting Multiple Sclerosis
MeSH terms: Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Sclerosis
Study type: Interventional
Phase: Phase 4

Summary: 
      This study was to find out if patients with Relapsing Remitting Multiple Sclerosis treated
      with Interferon beta-1a had an improved quality of life after treatment with Interferon
      beta-1a
    

Detailed description: 
      The study was an open-label, multi-center, international post-marketing study (phase 4).
      Eligible patients were interferon naïve patients suffering from relapsing MS. The duration of
      a subject's participation in the study was up to a maximum 26 months.
    

Intervention name(s): Interferon beta-1a
Intervention type(s): Drug
Intervention description(s): IM injection
Intervention MeSH terms: Interferons; Interferon-beta; Interferon beta-1a
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Multiple Sclerosis; Avonex; Interferon beta-1a
A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwise Healthy Smokers
Condition: Substance Dependence
MeSH terms: Substance-Related Disorders
Study type: Interventional
Phase: Phase 1

Summary: 
      Study to investigate the safety, tolerability and pharmacokinetics of GSK598809 in otherwise
      healthy volunteers. This study is required because this drug is being developed for the
      treatment of nicotine dependence. It is important to evaluate how this drug interacts in
      healthy smokers. The study is planned to consist of a single part, with 4 dosing periods.
      Subjects will receive 3 escalating doses of GSK598809 and 1 dose of placebo. There will be at
      least 1 week of wash out between doses. In each dosing period 14 subjects will receive
      escalating doses and 4 subjects will receive placebo. The actual doses used will be
      determined based on the safety/ tolerability and pharmacokinetics during the previous dose.
      It is expected that the duration of this study will be approximately 10 weeks.
    


Intervention name(s): GSK598809; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): GSK598809 capsules will be available with dose strengths of 5 milligrams and 25 milligrams, administered orally with water.; Placebo capsules will be administered orally with water.
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: Tolerability; dose escalation; GSK598809; Pharmacodynamics; Safety; single; placebo; Smokers; Pharmacokinetics
A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause
Condition: Hot Flashes
MeSH terms: Hot Flashes
Study type: Interventional
Phase: Phase 3

Summary: 
      This study is for women in menopause with hot flashes. Menopause, a normal part of aging, is
      the time of a woman's last period. Hot flashes can interrupt a woman's daily life. The
      purpose of this study is to find out how safe it is for these women to take fezolinetant long
      term (up to 52 weeks). To do that, the study will look at the number and severity of the
      "adverse events." Those are the side effects that study participants have while they are in
      the study. The study treatment is fezolinetant (1 tablet of fezolinetant) once a day. The
      study participants will take study treatment for 52 weeks. At weeks 2 and 4 and then once a
      month, the study participants will go the hospital or clinic for a check-up. They will be
      asked about medications, side effects and how they feel. Other checks will include physical
      exam and vital signs (heart rate, temperature and blood pressure). Blood and urine will be
      collected for laboratory tests. At some study visits, study participants will complete
      questionnaires that are about their quality of life. Study participants who still have their
      uterus will have 2 more tests done at the first and last study visits. One of the 2 tests is
      endometrial biopsy. This test involves removing a small amount of tissue from the inside
      lining of the uterus. The tissue is then checked under a microscope. The other test is
      transvaginal ultrasound. It uses sound waves to create pictures of the organs in the pelvis.
      The sound waves are transmitted by a probe (transducer), which is placed inside the vagina.
      Study participants may have a screening mammogram done at the first and/or last study visit.
      A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study
      participants who did not have this test done in the last 12 months will have it done at the
      first study visit. They will have it done at the last study visit if they are due for their
      screening mammogram and their own doctor agrees. The last check-up at the hospital or clinic
      will be 3 weeks after the last dose of study treatment.
    

Detailed description: 
      The study will consist of a screening period, a 52-week treatment period and a follow-up
      visit, 3 weeks after the last dose of study drug.
    

Intervention name(s): Fezolinetant
Intervention type(s): Drug
Intervention description(s): Oral
Other intervention name(s): ESN364; VEOZAH
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Vasomotor Symptoms; menopause; fezolinetant; ESN364
A Study to Evaluate the Safety and Use of Human Rhinovirus in Healthy and Asthmatic Participants (MK-0000-218)
Condition: Asthma
MeSH terms: Asthma
Study type: Interventional
Phase: Phase 1

Summary: 
      The purpose of this study is to establish the safety and tolerability of Unbiased Biomarkers
      for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) human rhinovirus 16 (RV16UB)
      in healthy and asthmatic participants, and to identify an appropriate dosage of RV16UB in
      order to study biomarkers in asthmatic participants. The study is divided into 2 parts. Part
      1 is a dose-finding study where healthy participants, and asthmatic participants, who were
      either treated or not treated with a class of long-acting beta antagonists (LABA) will be
      recruited to undergo nasal challenge with increasing doses of RV16UB. Part 2 is a biomarker
      study where mild to moderate asthmatics undergo challenge with the most appropriate dose of
      RV16UB identified in Part 1, based on tolerability and viral effects. .
    


Intervention name(s): RV16UB; LABA
Intervention type(s): Biological; Drug
Intervention description(s): RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.; Asthmatic participants were treated with LABA as part of their standard of care
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Diagnostic
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c
Condition: Irritable Bowel Syndrome With Constipation; Irritable Bowel Syndrome
MeSH terms: Irritable Bowel Syndrome; Syndrome; Constipation
Study type: Interventional
Phase: Phase 2

Summary: 
      This study will evaluate the safety, tolerability and pharmacodynamics of the investigational
      drug DDP733 in treating subjects with IBS-c. A placebo control will be utilized.
    


Intervention name(s): DDP733
Intervention type(s): Drug
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double
Primary purpose: Treatment
Keywords: IBS; IBS-c